{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:48:08Z","timestamp":1792291688795,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,15]],"date-time":"2015-07-15T00:00:00Z","timestamp":1436918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81402788"],"award-info":[{"award-number":["81402788"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"crossref","award":["20141115"],"award-info":[{"award-number":["20141115"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.apsb.2015.07.002","type":"journal-article","created":{"date-parts":[[2015,9,2]],"date-time":"2015-09-02T11:21:33Z","timestamp":1441192893000},"page":"431-441","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Adenine: an important drug scaffold for the design of antiviral agents"],"prefix":"10.1016","volume":"5","author":[{"given":"Changyuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2015.07.002_bib1","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.2174\/1381612033453668","article-title":"Phosphonomethoxyalkyl analogs of nucleotides","volume":"9","author":"Hol\u00fd","year":"2003","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.apsb.2015.07.002_bib2","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd1877","article-title":"Acyclic nucleoside phosphonates: a key class of antiviral drugs","volume":"4","author":"de Clercq","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2015.07.002_bib3","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/med.20149","article-title":"Antiviral drug discovery: ten more compounds, and ten more stories (part B)","volume":"29","author":"de Clercq","year":"2009","journal-title":"Med Res Rev"},{"key":"10.1016\/j.apsb.2015.07.002_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.antiviral.2009.10.005","article-title":"In search of a selective therapy of viral infections","volume":"85","author":"de Clercq","year":"2010","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2015.07.002_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/095632029700800101","article-title":"HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogs: a review of their pharmacology and clinical potential in the treatment of viral infections","volume":"8","author":"Naesens","year":"1997","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.apsb.2015.07.002_bib6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2893.2000.00192.x","article-title":"adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture","volume":"7","author":"Ying","year":"2000","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.apsb.2015.07.002_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.7326\/0003-4819-150-2-200901200-00101","article-title":"Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference","volume":"150","author":"Shamliyan","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.apsb.2015.07.002_bib8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0166-3542(92)90084-I","article-title":"Synthesis and in vitro evaluation of a phosphonate prodrug: bis(pivaloyloxymethyl) 9-(2-phosphonylmethoxyethyl)adenine","volume":"19","author":"Starrett","year":"1992","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2015.07.002_bib9","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.bmcl.2007.11.126","article-title":"Synthesis and anti-HIV activity of 2\u2032-fluorine modified nucleoside phosphonates: analogs of GS-9148","volume":"18","author":"Mackman","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2015.07.002_bib10","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.bmcl.2007.11.125","article-title":"Synthesis and anti-HIV activity of GS-9148(2\u2032-Fd4AP), a novel nucleoside phosphonate HIV reverse transcriptase inhibitor","volume":"18","author":"Boojamra","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2015.07.002_bib11","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1128\/AAC.01215-07","article-title":"Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131","volume":"52","author":"Cihlar","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2015.07.002_bib12","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1016\/j.bmc.2010.03.041","article-title":"Discovery of GS-9131: design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148","volume":"18","author":"Mackman","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2015.07.002_bib13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1081\/NCN-100002338","article-title":"Practical synthesis, separation, and stereochemical assignment of the PMPA pro-drug GS-7340","volume":"20","author":"Chapman","year":"2001","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.apsb.2015.07.002_bib14","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1128\/AAC.49.5.1898-1906.2005","article-title":"Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue","volume":"49","author":"Lee","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2015.07.002_bib15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.7326\/0003-4819-119-4-199308150-00011","article-title":"Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis","volume":"119","author":"Wong","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.apsb.2015.07.002_bib16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/10428199109103394","article-title":"2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia","volume":"5","author":"Saven","year":"1991","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.apsb.2015.07.002_bib17","first-page":"838","article-title":"Synthesis of 2-chloro-2\u2032-5\u2032-dideoxy-5\u2032-difluoromethylphosphinyladenosine: a nonhydrolyzable isosteric, isopolar analog of 2-chlorodeoxyadenosine mono phosphate","volume":"7","author":"Levy","year":"1996","journal-title":"Synthesis"},{"key":"10.1016\/j.apsb.2015.07.002_bib18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1600-0609.1999.tb01114.x","article-title":"2-Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland","volume":"62","author":"Robak","year":"1999","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.apsb.2015.07.002_bib19","first-page":"155","article-title":"Treatment of hairy-cell leukemia: current views","volume":"36","author":"Tallman","year":"1999","journal-title":"Semin Hematol"},{"key":"10.1016\/j.apsb.2015.07.002_bib20","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1021\/jm100030u","article-title":"2-MeS-\u03b2,\u03b3-CCl2-ATP is a potent agent for reducing intraocular pressure","volume":"53","author":"Eliahu","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2015.07.002_bib21","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1135\/cccc19942069","article-title":"Synthesis of some 2\u2032-C-alkyl derivatives of 9-(2-phosphonomethoxyethyl) adenine and related-compounds","volume":"59","author":"Dvor\u02c7\u00e1kov\u00e1","year":"1994","journal-title":"Collect Czechoslov Chem Commun"},{"key":"10.1016\/j.apsb.2015.07.002_bib22","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1021\/jm9811256","article-title":"Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogs. 1. Derivatives substituted at the carbon atoms of the base","volume":"42","author":"Hol\u00fd","year":"1999","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2015.07.002_bib23","unstructured":"Krawczyk SH. Nucleobase phosphonate analogs for antiviral treatment. US Patent WO2005\/12324A2; 2005 March 17"},{"key":"10.1016\/j.apsb.2015.07.002_bib24","unstructured":"Averet DR. Nucleoside phosphonate derivatives useful in treatment of HIV infection. US Patent WO2005\/79812A1; 2005."},{"key":"10.1016\/j.apsb.2015.07.002_bib25","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1135\/cccc20001357","article-title":"Synthesis of acyclic nucleotide analogs derived from 2-amino-6-C-substituted purines via cross-coupling reactions of 2-amino-9-{2-[(diisopropoxyphosphoryl)methoxy]ethyl}-6-halopurines with diverse organometallic reagents","volume":"65","author":"C\u00a8esnek","year":"2000","journal-title":"Collect Czechoslov Chem Commun"},{"key":"10.1016\/j.apsb.2015.07.002_bib26","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.bmc.2007.10.010","article-title":"Synthesis of guanidino analogs of PMPDAP and their immunobiological activity","volume":"16","author":"C\u00a8esnek","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2015.07.002_bib27","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1021\/jm050473m","article-title":"Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl) adenine against cytomegalovirus and orthopoxviruses","volume":"49","author":"Beadle","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2015.07.002_bib28","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1016\/j.bmc.2011.06.009","article-title":"Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)-propyl] nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication","volume":"19","author":"Valiaeva","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2015.07.002_bib29","doi-asserted-by":"crossref","first-page":"6825","DOI":"10.1021\/jm901828c","article-title":"Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-2, 6-diaminopurine (HPMPDAP) as anti-poxvirus agents","volume":"53","author":"Kre\u010dmerov\u00e1","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2015.07.002_bib30","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1021\/jm00038a015","article-title":"Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA)","volume":"37","author":"Starrett","year":"1994","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2015.07.002_bib31","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0960-894X(01)00128-7","article-title":"Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA","volume":"11","author":"Ballatore","year":"2001","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2015.07.002_bib32","doi-asserted-by":"crossref","first-page":"8079","DOI":"10.1021\/jm050641a","article-title":"cycloSal\u2013PMEA and cycloAmb\u2013PMEA: potentially new phosphonate prodrugs based on the cycloSal\u2013pronucleotide approach","volume":"48","author":"Meier","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2015.07.002_bib33","doi-asserted-by":"crossref","first-page":"7799","DOI":"10.1021\/jm060030y","article-title":"Canard B, et al. Synthesis, in vitro antiviral evaluation, and stability studies of novel \u03b1-borano-nucleotide analogs of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine","volume":"49","author":"Barral","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2015.07.002_bib34","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1016\/0040-4039(91)80164-2","article-title":"Synthesis of new carbocyclic phosphonate analogs of dideoxypurine nucleotides","volume":"32","author":"Wolff-Kugel","year":"1991","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.apsb.2015.07.002_bib35","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0014-5793(97)00616-9","article-title":"Conversion of 2\u0384,3\u0384-dideoxyadenosine (ddA) and 2\u0384,3\u0384-didehydro-2\u0384,3\u0384-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus","volume":"410","author":"Balzarini","year":"1997","journal-title":"FEBS Lett"},{"key":"10.1016\/j.apsb.2015.07.002_bib36","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1042\/bj0610116","article-title":"A spectrophotometric method for the determination of creatine phosphokinase and myokinase","volume":"61","author":"Oliver","year":"1955","journal-title":"Biochem J"},{"key":"10.1016\/j.apsb.2015.07.002_bib37","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0021-9258(18)72324-7","article-title":"The r\u00f4le of myokinase in transphosphorylations I. The enzymatic phosphorylation of hexoses by adenyl pyrophosphate","volume":"148","author":"Colowick","year":"1943","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2015.07.002_bib38","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0021-9258(18)55953-6","article-title":"Myokinase and adenosinetriphosphatase in oxidative phosphorylation","volume":"191","author":"Kielley","year":"1951","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2015.07.002_bib39","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0021-9258(18)71978-9","article-title":"Adenylpyrophosphatase and myokinase","volume":"153","author":"Kalckar","year":"1944","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2015.07.002_bib40","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S0960-894X(00)80413-8","article-title":"Carbocyclic phosphonate analogs of 2\u2032,3\u2032-dideoxyadenosine-5\u2032-monophosphate as substrates of 5-phosphoribosyl-1-pyrophosphate (PRPP) synthetate","volume":"2","author":"Nav\u00e9","year":"1992","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2015.07.002_bib41","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1080\/15257779508010709","article-title":"Kinetic properties of adenine nucleotide analogs against purified 5-phosphoribosyl-1-pyrophosphate synthetases from E. Coli, rat liver and human erythrocytes","volume":"14","author":"Balzarini","year":"1995","journal-title":"Nucleosides Nucleotides"},{"key":"10.1016\/j.apsb.2015.07.002_bib42","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1021\/bi982279q","article-title":"Kinetic mechanism of uracil phosphoribosyltransferase from Escherichia coli and catalytic importance of the conserved proline in the PRPP binding site","volume":"38","author":"Lundegaard","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.apsb.2015.07.002_bib43","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1021\/jm049029u","article-title":"Design, synthesis, and antiviral activity of adenosine 5\u2032-phosphonate analogs as chain terminators against Hepatitis C virus","volume":"48","author":"Koh","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2015.07.002_bib44","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/10426509908546299","article-title":"Highly potent bisphosphonate ligands for phosphoglycerate kinase and protein binding studies","volume":"144\u2013146","author":"Jakeman","year":"1999","journal-title":"Phosphorus Sulfur"},{"key":"10.1016\/j.apsb.2015.07.002_bib45","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.bmc.2008.12.028","article-title":"Design, synthesis, and anti-HIV activity of 4\u2032-modified carbocyclic nucleoside phosphonate reverse transcriptase inhibitors","volume":"17","author":"Boojamra","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2015.07.002_bib46","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1016\/j.bmcl.2013.03.095","article-title":"Evaluation of 2'-\u03b1-fluorine modified nucleoside phosphonates as potential inhibitors of HCV polymerase","volume":"23","author":"Parrish","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2015.07.002_bib47","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/cmdc.201300035","article-title":"Synthesis and anti-herpetic activity of phosphoramidate ProTides","volume":"8","author":"Maiti","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.apsb.2015.07.002_bib48","doi-asserted-by":"crossref","first-page":"6328","DOI":"10.1016\/j.bmcl.2011.08.113","article-title":"Antiviral activity of novel 2\u2032-fluoro-6\u2032-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants","volume":"21","author":"Wang","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2015.07.002_bib49","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.bmcl.2012.11.027","article-title":"2\u2032-Fluoro-6\u2032-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action","volume":"23","author":"Rawal","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2015.07.002_bib50","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.5012\/bkcs.2010.31.9.2473","article-title":"Synthesis and antiviral evaluation of 1\u2032-branched-5\u2032-norcarbocyclic adenosine phosphonic acid analogs","volume":"31","author":"Oh","year":"2010","journal-title":"Bull Korean Chem Soc"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383515001057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383515001057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T06:45:15Z","timestamp":1653115515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383515001057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S2211383515001057"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2015.07.002","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adenine: an important drug scaffold for the design of antiviral agents","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2015.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}